A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
|Articles|June 19, 2020
CPhI North America Canceled
Author(s)BioPharm International Editors
The decision was made in order to give exhibitors enough time to adjust their plans in the wake of the continuing spread of COVID-19.
Advertisement
CPhI North America, organized by Informa Markets, announced on June 19, 2020 that the CPhI event, which was originally scheduled for Sept.9–11, 2020 at the Pennsylvania Convention Center in Philadelphia, PA, will be canceled. The decision was made in order to give exhibitors enough time to adjust their plans in the wake of the continuing spread of COVID-19, an Informa press release said.
“This conclusion was not one that was reached easily, but with the health and safety of our community in mind, we have made the proactive decision to act now,” the press release said. “We understand how important CPhI North America is to the industry and how much effort goes into preparing for it and so, in this difficult time, we would like to thank our community for its understanding and support.”
CPhI also announced it will host a series of webinars in place of the in-person show.
“While our live event has been cancelled, learning never stops,” the press release said. “We have a series of webinars on trending topics coming up soon, and we’ll keep you posted on the details as we finalize them.”
Source:
Advertisement
Related to this article
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
T-Therapeutics closed an oversubscribed $133 million Series B backed by Eli Lilly, JJDC, and others. The funding will take its first T-cell receptor bispecifics in cancer and autoimmune disease into clinical trials.
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Healthy-volunteer data show sustained TL1A suppression and a profile supporting infrequent subcutaneous dosing. Caldera also licensed a second bispecific, targeting IL-17 and TL1A, from Qyuns Therapeutics.
Advertisement
Advertisement
Trending on BioPharm International
1
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
2
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
3
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
4
Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks
5